{
    "2019-03-25": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Were Hedge Funds Right About Novartis AG (NVS)?",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Novartis",
                        "AG"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Genentech",
                        "tumor-agnostic",
                        "cancer drug",
                        "Novartis",
                        "East Bay"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Alcon Inc. -- Moody's assigns Baa2 issuer rating to Alcon; stable outlook",
                "features": {
                    "keywords": [
                        "Alcon Inc.",
                        "Moody's",
                        "Baa2",
                        "issuer rating",
                        "stable outlook"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}